Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases

Matthew Bates1,2, Ben J. Marais3, and Alimuddin Zumla4

1University of Zambia-University College London Medical School (UNZA-UCLMS) Research and Training Project5, University Teaching Hospital, Lusaka RW1X, Zambia
2Center for Clinical Microbiology, Department of Infection, Division of Infection and Immunity, University College London, London, United Kingdom
3Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI) and The Children’s Hospital at Westmead, Sydney Medical School, University of Sydney, Sydney, Australia
4National Institute of Health Research, Biomedical Research Centre, Royal Free Campus Rowland Hill St, University College London Hospitals, London NW3 2PF, United Kingdom

Correspondence: a.zumla@ucl.ac.uk

The 18th WHO Global Tuberculosis Annual Report indicates that there were an estimated 8.6 million incident cases of tuberculosis (TB) in 2012, which included 2.9 million women and 530,000 children. TB caused 1.3 million deaths including 320,000 human immunodeficiency virus (HIV)-infected people; three-quarters of deaths occurred in Africa and Southeast Asia. With one-third of the world’s population latently infected with Mycobacterium tuberculosis (Mtb), active TB disease is primarily associated with a break down in immune surveillance. This explains the strong link between active TB disease and other communicable diseases (CDs) or noncommunicable diseases (NCDs) that exert a toll on the immune system. Comorbid NCD risk factors include diabetes, smoking, malnutrition, and chronic lung disease, all of which have increased relentlessly over the past decade in developing countries. The huge overlap between killer infections such as TB, HIV, malaria, and severe viral infections with NCDs, results in a “double burden of disease” in developing countries. The current focus on vertical disease programs fails to recognize comorbidities or to encourage joint management approaches. This review highlights major disease overlaps and discusses the rationale for better integration of tuberculosis care with services for NCDs and other infectious diseases to enhance the overall efficiency of the public health responses.

During the past two decades, health priorities in developing countries have been determined primarily by the epidemics of killer infectious diseases, particularly tuberculosis (TB), HIV/AIDS (acquired immunodeficiency syndrome), and malaria. The 2013 WHO Global TB report estimates that 8.6 million TB cases occurred in 2012, causing 1.3 million deaths of which 320,000 were in HIV-infected people (WHO 2013). Three-quarters of TB deaths oc-
curred in Africa and Southeast Asia, with South Africa and India accounting for one-third of all deaths. An estimated 3 million people with active TB were either not diagnosed or diagnosed but not reported. Copresentation of severely ill patients with other communicable and noncommunicable diseases (NCDs) is a major cause of TB-associated deaths (Bates et al. 2012; Geneau and Hallen 2012; Remais et al. 2013) (Table 1).

The global burden of NCDs, particularly cancer, cardiovascular disease, diabetes, and chronic respiratory disease, accounts for nearly half of all disability and two-thirds of deaths worldwide (Beaglehole et al. 2011; WHO 2011). The prevalence of NCDs is increasing the fastest in low- and middle-income countries and impacting disproportionately on disadvantaged communities. In 2010, more than 2 million deaths attributable to NCDs occurred in sub-Saharan Africa, a 46% (95% CI 41–59) increase from 1990 (Lozano et al. 2012). In developing countries, major demographic shifts, urbanization, changing environmental factors, economic empowerment, and accompanying lifestyle changes have led to a rapid increase in NCDs (Lim et al. 2012). Undernutrition, tobacco use, the growing diabetes epidemic, and indoor air pollution are also impacting TB control adversely in Southeast Asian nations. In the sub-Saharan African context, the impact of the HIV epidemic is more significant on TB. So prevention and treatment policy and programming have to take these factors into account.

Table 1. Key messages

| TB comorbidity with noncommunicable diseases (NCDs) and other communicable diseases (CDs) | is highly prevalent in TB endemic regions of the world. Population attributable TB risk estimates for diabetes, malnutrition, smoking, excessive alcohol use, and HIV infection are high. |
| Traditional vertical (disease-specific) approaches to health care services delivery often fail to recognize potential synergies. Wider integration of TB control activities present opportunities to explore commonalities and optimize synergies without sacrificing recent gains or eroding the functionality of existing programs. |
| The lethal bidirectional interaction between TB and HIV coinfection in sub-Saharan Africa exemplifies the need for well-integrated approaches to disease management and control. |
| The looming threat of diabetes mellitus (DM) and TB also calls for bidirectional screening and the need to tackle a broader range of overlapping diseases in resource-poor countries. High levels of TB comorbidity in patients admitted to hospital with CDs or NCDs and in pregnant women attending antenatal clinics are easily overlooked in TB endemic areas. |
| Efficient integration of TB services should be encouraged, while maintaining some vertical elements to secure essential functions such as drug supply, monitoring and evaluation, and national surveillance, to a point in which the national TB program may be limited to a small central team providing general oversight. |
TUBERCULOSIS AND NONCOMMUNICABLE DISEASES

Diabetes

The epidemiological link between diabetes and TB is well established, but during the last half-century, populations that have developed high rates of diabetes (wealthier, overnourished, more sedentary working environments) have been distinct from those still dogged by rampant TB (poorer, undernourished, persistence of grueling manual working environments). Increasing industrialization and urbanization in developing countries are leading to growth in rates of diabetes, leading to a potentially cataclysmic confluence of NCDs (of which diabetes is one of the most common) and CDs (of which TB is the most common). In parts of India and China, this has already become a reality, as swathes of the traditionally rural populous flock to overcrowded dwellings in urban centers to take up minimum wage employment in poorly ventilated factories and mines (Li et al. 2012; Lin et al. 2012; Viswanathan et al. 2012).

Several large case-controlled and longitudinal cohort studies have shown that the relative odds of developing active TB ranges from two to eight in diabetic patients versus nondiabetic controls (reviewed by Dooley and Chaisson 2009). These studies were in different populations globally, controlling for the particular risk factors, which predominate in each study population. A recent meta-analysis concluded that diabetes patients were 3.1 times more likely to develop active TB than controls, although relative risk was lower in North American study populations (Jeon and Murray 2008). TB is also more likely in insulin-dependent versus non-insulin-dependent diabetes patients (Olmos et al. 1989; Swai et al. 1990; Leung et al. 2008).

Studies have shown a negative impact of diabetes on treatment outcomes including an up to fourfold increase in the risk of treatment failure (Mboussa et al. 2003; Morsy et al. 2003; Alisjahbana et al. 2007). Studies from Turkey and the United States following up patients for a shorter period suggest that diabetes is linked with modest delays in clearance (Guler et al. 2007; Restrepo et al. 2008), although one Indian study found that whereas diabetes patients were more likely to be smear-positive (which bodes well for diagnosis), they had higher smear conversion rates at 3 mo (Singla et al. 2006).

Table 2. Differences, similarities, and potential synergies between tuberculosis (TB) and noncommunicable diseases (NCDs)

<table>
<thead>
<tr>
<th>Differences and similarities</th>
<th>Tuberculosis</th>
<th>NCDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmissible</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Infection control important</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Need to prevent</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>POC testing problematic</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Curable</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Long-term treatment</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Major adherence issues</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Require lifestyle changes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Potential synergies

- Reciprocal screening for TB, other CDs (malaria, HIV) and NCDs
- Combined health messaging and communication strategies
- Coordinated human resource development/training opportunities
- Combined infrastructure development
- Cross-utilization of health care workers
- Unified point of care; avoids multiple clinic attendances
- Integrated recording/reporting systems
- Opportunities for community and user education/engagement
- Poverty alleviation strategies
- Creating an environment that sustains health and well-being

POC, point of care.
There are reports for and against an association between diabetes and drug-resistant tuberculosis (Dooley and Chaisson 2009), with possible explanations including delayed clearance resulting in routine switching to a two-drug regimen in patients who are still culture positive or lowered rifampicin levels in diabetes patients (Nijland et al. 2006). Among TB patients, having diabetes is linked with a significant increase in the risk of death (Dooley et al. 2009; Ismail and Bulgiba 2013). Very little of the available data comes from sub-Saharan African populations, where diabetes prevalence will increase over the next decade (Dooley and Chaisson 2009) and where TB and diabetes treatment decisions for significant numbers of patients will have to frequently accommodate antiretroviral therapy, which itself is associated with increased risk of TB (Marais et al. 2013). Diabetes mellitus (DM) increases the risk of active TB by a factor of 2 to 3. In addition, people with TB, who have diabetes, have been found to have worse TB treatment outcomes. The WHO and The International Union Against Tuberculosis and Lung Disease Framework for Collaborative Activities recommend screening for TB and diabetes simultaneously. The recommended collaborative activities, outcome indicators, and research areas for guiding public health policies for joint TB and diabetes care recommend screening for active TB in patients with diabetes and for diabetes in patients with TB to make

Figure 1. Estimates of population attributable to TB disease risk caused by HIV, undernutrition, smoking, diabetes, and alcohol abuse. AFR high HIV: African countries with high HIV prevalence. AFR low HIV: African countries with low/moderate HIV prevalence. CEUR: Central European countries. EME: Established market economies. EMR: Eastern Mediterranean region. LAC: Latin American countries. SEAR: Southeast Asian region. WPR: Western Pacific region (except EME). Population attributable fraction (PAF) = \( \frac{\text{prevalence} \times (\text{relative risk} - 1)}{\text{prevalence} \times (\text{relative risk} - 1) + 1} \). Point estimates of relative risk from systematic reviews were used. When prevalence was only available for adults, the prevalence in adults was adjusted for proportion of population under the age of 15 to estimate the total population PAF. HIV (human immunodeficiency virus infection): Relative risk = 27. Undernutrition (undernutrition): Relative risk = 3.2 (for BMI 16 vs. BMI 25). Diabetes (DM, diabetes mellitus): Relative risk = 3.1. Alcohol abuse: Relative risk = 2.9. Prevalence data: Average of prevalence of heavy drinking in China, Brazil, India, Nigeria, Pakistan, Russia, South Africa, and Thailand. Smoking (cigarette smoking): Relative risk = 2.0 (current vs. never smokers). (Adapted from Lönnroth et al. 2010 and Creswell et al. 2011.)
earlier diagnoses, which in turn may lead to better treatment outcomes and control of both diseases (Table 3) (WHO/IUA TBLD 2011).

**Malnutrition**

Malnutrition is a risk factor for all infectious diseases because it impairs immunity. Both protein calorie malnutrition (PCM) and micronutrient deficiencies can cause immune suppression through a variety of mechanisms, as reviewed in Bhaskaram (2002) and Schaible and Kaufmann (2007). Chronic malnutrition has a great impact on chronic infectious diseases such as HIV and TB, which require constant immune surveillance and control. The prevalence of malnutrition, generally defined by a BMI of $<18.5 \text{ kg/m}^2$, among adult pulmonary TB patients can range from 42% to 80% (Kennedy et al. 1996; Zachariah et al. 2002; Dodor 2008; Mupere et al. 2012; Bhargava et al. 2013). In the African studies, the prevalence of malnutrition was lower among women, whereas in the Indian study, it was lower among men. These studies did not compare the prevalence of malnutrition among TB patients with that of the general population, but they did look at the cause of malnutrition on TB treatment outcomes. Three of these studies showed improvements in nutritional status with TB treatment, but weight gain did not correlate with microbiological response and significant numbers of patients cured of TB were still underweight at 12 mo, indicating the overriding influence of socioeconomic factors (Kennedy et al. 1996; Zachariah et al. 2002; Dodor 2008; Bhargava et al. 2013). A Korean study also found malnutrition to be associated with poorer outcomes in disseminated TB (Kim et al. 2008). One Tanzanian study identified TB as an important correlate of wasting, independent of HIV (Villamor et al. 2006), and Malawian, Ugandan, and Indian studies found that severe malnutrition on admission was independently linked with increased risk of early mortality (Zachariah et al. 2002; Mupere et al. 2012; Bhargava et al. 2013). A Latvian study found that being underweight was linked with worse outcomes and increased mortality in multidrug-resistant (MDR)-TB (Podewils et al. 2011).

Children primarily acquire active TB from adults with whom they live, and so one would expect the prevalence of malnutrition among children with TB to be similar if not higher than among adult TB patients, with households affected by malnutrition more likely to suffer transmission events from infected adults to children. A study from Pakistan found 51% of children initiating TB therapy to have PCM (Uddin Siddiqui et al. 2010), and there is a need for more research to evaluate possible interventions to cotreat malnutrition and tuberculosis and to assess to what degree nutritional interventions might be able to prevent the development of active TB in high-risk children (Jaganath and Mupere 2012).

**TUBERCULOSIS AND OTHER COMMUNICABLE DISEASES**

**HIV/AIDS**

In the early 1990s, researchers started to ask questions about the effect of HIV coinfection on TB prevalence, drug reactions, and treatment outcomes. A U.S. study of prisoners was the first paper in which the term "coinfection" was used with respect to HIV and TB (Salive et al. 1990). Subsequent studies in various patient groups showed significantly higher prevalence of HIV-1 infection in TB patients (Singh et al. 1993; Greenberg et al. 1994; Kivihya-Ndugga et al. 1994a), including children (Chintu et al. 1993), showing associations with more severe disease (Kivihya-Ndugga et al. 1994a), more advanced immune suppression (Kivihya-Ndugga et al. 1994b; Martin et al. 1995), and drug reactions (Pozniak et al. 1992).

In the subsequent two decades, the HIV epidemic has expanded dramatically in some countries, dragging both pulmonary and extrapulmonary TB in its wake, fueling a fivefold increase in TB notification rates between 1990 and 2010 in sub-Saharan Africa, which bears 80% of the global HIV disease burden. HIV increases TB risk by 20- to 40-fold and TB accounts for 25% of HIV-related deaths worldwide—the single largest cause. The WHO Global Tuberculosis Report 2013 states that 13%
Table 3. Recommended collaborative activities, outcome indicators, and research areas for guiding public health policies for joint TB and diabetes care

<table>
<thead>
<tr>
<th>Area</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A. Establish mechanisms for collaboration</strong></td>
<td><strong>Recommendation 1:</strong> Joint coordination should be established at regional, district, and/or local levels (sensitive to country-specific factors), with representation from all relevant stakeholders. A joint plan for diabetes and TB activities should be drawn up and reflected in national plans on noncommunicable diseases and TB, respectively.</td>
</tr>
<tr>
<td>A.1. Setup means of coordinating diabetes and TB activities</td>
<td><strong>Recommendation 2:</strong> There should be TB surveillance among diabetes patients in settings with medium to high TB burden.</td>
</tr>
<tr>
<td>A.2. Conduct surveillance of TB disease prevalence among people with diabetes in medium and high TB burden settings</td>
<td><strong>Recommendation 3:</strong> There should be surveillance of diabetes among TB patients in all countries.</td>
</tr>
<tr>
<td>A.3. Conduct surveillance of diabetes prevalence in TB patients in all countries</td>
<td><strong>Recommendation 4:</strong> Where diabetes and TB collaboration is being established, programs for both diseases should agree on a core set of indicators and data collection tools for the monitoring and evaluation of collaborative activities. Diabetes programs should explore the possibility of adapting the directly observed therapy (DOT) system to monitor and report cases and treatment outcomes.</td>
</tr>
<tr>
<td>A.4. Conduct monitoring and evaluation of collaborative diabetes and TB activities</td>
<td><strong>Recommendation 5:</strong> At a minimum, people with diabetes should be asked about the presence of cough (lasting &gt;2 wk) at the time of diabetes diagnosis, and if possible at each regular check-up for diabetes. Those with positive symptoms should be examined as per national guidelines. Other diagnostic procedures, such as those for extrapulmonary TB, should be pursued rigorously as per national guidelines.</td>
</tr>
<tr>
<td><strong>B. Detect and manage TB in patients with diabetes</strong></td>
<td><strong>Recommendation 6:</strong> Screening for active TB on broader indications (e.g., in all people diagnosed with diabetes, regardless of symptoms) should be explored as part of the research agenda for improved TB diagnosis among people with diabetes.</td>
</tr>
<tr>
<td>B.1. Intensify detection of TB among people with diabetes</td>
<td><strong>Recommendation 7:</strong> A referral system should be established so that patients with suspected TB are promptly sent to TB diagnostic and treatment centers and evaluated in accordance with the guidelines of the national TB control program.</td>
</tr>
<tr>
<td>B.2. Ensure TB infection control in health-care settings where diabetes is managed</td>
<td><strong>Recommendation 8:</strong> Tuberculosis case finding should be intensified by increasing the awareness and knowledge of the interactions between diabetes and TB, including joint risk factors, among health-care workers and populations they serve.</td>
</tr>
</tbody>
</table>
| B.3. Ensure high-quality TB treatment and management in people with diabetes | **Recommendation 9:** Each health-care facility, including diabetes clinics, should have an infection control plan (including a plan for TB infection control), which includes administrative and environmental control **Continued**

M. Bates et al.
(1.1 million) of 8.6 million people who developed TB in 2012 are coinfected with HIV (WHO 2013). With respect to HIV/TB, the report highlights some modest improvements—coverage of ART (antiviral therapy) and cotrimoxazole preventative therapy have improved among HIV-positive TB patients in recent years. Isoniazid preventative therapy (IPT) was provided to one-third of all new HIV cases diagnosed in 2012, although 50% are likely eligible. It remains unclear how appropriate this is in extremely high-burden settings.

As one of five key priority areas, the report highlights the need for improved coverage of dual HIV/TB testing, which in some countries approaches 100%, indicating what is possible. Low HIV burden countries have had more problems, or shown less initiative, in promoting HIV counseling and testing among newly diagnosed TB patients. In the Africa region, the epicenter of the HIV pandemic, up to 77% of TB patients are coinfected with HIV, and the rate of TB patients who have undergone HIV testing has increased dramatically in recent years. Seven high-burden countries, mainly from Eastern and Southern Africa, have HIV testing rates in TB clinics higher than 90%, lead by Zambia, the only country to test virtually all notified TB

---

**Table 3. Continued**

<table>
<thead>
<tr>
<th>Area</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>measures to reduce transmission of TB within this setting. These measures should adhere to WHO’s International guidelines for TB infection control. <strong>Recommendation 10:</strong> Treatment and case management of TB in people with diabetes should be provided in accordance with existing TB treatment guidelines and international standards. The same TB treatment regimen should be prescribed to people with diabetes as for people without diabetes.</td>
</tr>
</tbody>
</table>

**C. Detect and manage diabetes in patients with TB**

**C.1. Screen TB patients for diabetes**

**C.2. Ensure high-quality diabetes management among TB patients**

**Recommendation 11:** TB patients should be screened for diabetes at the start of treatment. Type of screening and diagnostic tests should be adapted to the context of local health systems and the availability of resources, while awaiting additional evidence on the best screening and diagnostic approach.

**Recommendation 12:** Management of diabetes in TB patients should be provided in line with existing guidelines.

1. Joint TB and diabetes plan in place
2. Number and proportion of people with diagnosed diabetes who have been screened for chronic cough
3. Number and proportion of people with diabetes who have been tested for TB (radiography, sputum smear microscopy, culture, Xpert MTB/Rif Assay, etc.)
4. Prevalence of TB among people with diabetes
5. Number and proportion of people with TB who have been screened for diabetes
6. Prevalence of diabetes among people with TB
7. TB treatment outcomes among people with diabetes

Data adapted from WHO/IUATBD 2011.
cases for HIV. Because HIV status may inform on treatment decisions in comorbid patients (e.g., toxicities and pharmacokinetic interactions of TB and ART or other drugs), Diagnostic Counseling and Testing (DCT) or “opt out” strategies have been instigated in some in-patient settings and high-risk groups. In recent years, WHO has invested in improved data collection systems for TB/HIV; however, in many countries, there is still a great need for improved data collection, with data from both HIV and TB programs irreconcilable in some cases. There are also still significant patient groups that go under the radar and are not captured. For example, data from Zambia shows that TB is frequently missed in a range of hospitalized patients, attributable to overriding symptoms indicative of one or more comorbid communicable or noncommunicable diseases (Bates et al. 2012). Those who are discharged should be referred back to their community TB treatment center, but there are no funds to follow up such cases, and the large number of missed TB patients who die shortly after admission are not reported to the National Tuberculosis Programmes (NTPs). Most importantly, rates of MDR-TB within this high morbidity and mortality, HIV-positive in-patient group may approach 10%, resulting in possible gross underestimation of MDR-TB cases in what are currently considered to be relatively low MDR-TB prevalence countries (Bates et al. 2012).

The treatment of HIV and TB in coinfected patients is potentially complicated by toxicities and pharmacokinetic interactions between the drugs used in anti-TB and ART, but because of the considerable number of drugs available, regimens can often be adjusted to reduce side effects and nonadherence (Arentz et al. 2012). HIV-infected TB patients initiated on ART benefit from increased survival and cure rates, whether on first-line (Gengiah et al. 2011) or second-line anti-TB therapy (Arentz et al. 2012). WHO recommend that ART should be commenced as soon as possible after initiating TB treatment, especially in patients with CD4 counts of <50 cells/mL, but early mortality remains a significant problem in patients initiating ART and trials are under way to evaluate the possible benefits of presumptive TB treatment in high-risk patients with very low CD4 counts (Zumla et al. 2013).

In sub-Saharan Africa, TB now supersedes obstetric causes of death in HIV-infected pregnant women, with vertical transmission of TB occurring in up to 15% of neonates born to mothers suffering from HIV/TB coinfection (Adhikari et al. 2011; Bekker et al. 2012). With HIV-infected persons living longer on ART (Volberding and Deeks 2010; Ullrich et al. 2011), and the huge success of interventions to reduce mother-to-child-transmission (MTCT) of HIV (Sturt et al. 2010), the number of children born to HIV/TB coinfected mothers is set to increase and so is the burden of neonatal TB. There is a need for more research into possible ways to prevent MTCT of TB and on how best to diagnose and treat TB in the HIV-exposed neonate, which compounds just about all diagnostic and treatment challenges seen in other patient groups.

Malaria

Although there is considerable literature on HIV/tuberculosis and HIV/malaria coinfections and comorbidity, there has been distinctly less attention given to both clinical and immunological interactions between TB and malaria. Unlike HIV, both Mycobacterium tuberculosis (Mtb) and Plasmodium species are ancient pathogens that have coevolved in the same human populations over millennia, with molecular evidence for coinfections shown in 2000–3000-yr-old mummified remains from lower Egypt (Lalremruata et al. 2013). When two chronic pathogens have coevolved in the same population, it is possible (if not highly likely) that they have evolved mutually beneficial “win–win” strategies, to aid their own persistence and transmission. Could there be molecular synergies between plasmodium and Mtb that contribute to each other’s persistence in endemic regions (Enwere et al. 1999)?

Animal model studies suggest infection with malaria induces immune responses that impair host resistance to chronic TB infection, with
exacerbated leukocyte infiltrates, tissue pathology, and hypercytokinemia accompanied by altered T-cell responses, pointing to malaria-induced dysregulation of innate and adaptive antimycobacterial defenses (Hawkes et al. 2010; Mueller et al. 2012). Other animal model studies have shown that coinfected mice were less able to inhibit \textit{Mtb} growth in lungs, spleen, and liver (Scott et al. 2004) and that TB and malaria trigger similar innate immune responses such as the heme oxygenase 1 pathway, enhancing the efficiency of the liver stage in the \textit{Plasmodium} life cycle (Sinnis and Ernst 2008). Conversely, it is also possible that under certain circumstances, coinfecting pathogens may possess competitive strategies, with one study showing \textit{Mtb}-induced protective effects against lethal murine malaria (Page et al. 2005). Another study showed that murine malaria infection did not have any effect on vaccine-induced TB immunity (Parra et al. 2011).

There are few studies that document cross-sectional prevalence of malaria in TB patients, with rates ranging from 5% to 37%, because of differences in study location, population, and definitions used (Range et al. 2007; Valadas et al. 2013). Malaria infection can inhibit TB interferon-\(\gamma\) release assays (IGRAS) (Banfield et al. 2012), but this is mute, in that these diagnostics are not generally recommended for use in high-burden populations. There are also some potential drug interactions that should be considered when treating coinfected patients. Fluoroquinolones are contraindicated with other drugs that prolong ventricular repolarization, recorded as lengthening of the QT interval on an electrocardiogram (Murphy et al. 2012). Induction of the hepatic cytochrome P450 enzyme system by rifampicin results in a halving in the serum concentrations of artemisinin and its derivatives, complicating the concurrent management of TB and acute malaria. There is a case report in the literature of malaria and TB co-infection presenting as sepsis in a neonate (Thapa et al. 2010). This is of potential impact in that blood cultures from neonates with suspected sepsis are often negative, with testing for nonbacterial infections such as malaria and TB often overlooked.

**Influenza**

Data from the 1918 influenza epidemic suggested a clear association with increased risk for TB-related disease and death during this time period. Mouse models have shown that prior exposure to influenza A impairs immune responses to \textit{Mtb} infection and decreases survival (Redford et al. 2014), possibly through down-regulated MHC (major histocompatibility complex) expression on dendritic cells and reduced activation of CD4 and CD8 T cells to clear mycobacteria (Florido et al. 2013). A similar murine study found influenza had little effect on mycobacterial load (Co et al. 2006). Clinical data from Southeast Asia does not support an association between influenza and TB (de Paus et al. 2013; Noh et al. 2013; Roth et al. 2013). Even studies from high HIV burden patient groups in South Africa have found TB co-infection in the 2009 H1N1 outbreak to be rare in influenza deaths (10%), with pregnancy being a more potent risk factor (Archer et al. 2009).

Other acute respiratory tract infections are also likely to increase patients’ vulnerability to develop \textit{Mtb} infection or disease, and may partially explain some of the seasonal variability observed in temperate regions. A randomized controlled trial to assess the impact of pneumococcal vaccination showed decreased rates of culture-confirmed and clinically diagnosed TB in vaccinated children (Moore et al. 2010). Case ascertainment bias could not be excluded, because unvaccinated children had more frequent respiratory illness warranting diagnostic work-up, but it offers the intriguing possibility that pneumococcal co-infection may increase children’s vulnerability to develop active TB.

**Helminths**

There is increasing recognition that a high exposure to pathogens in poor communities living in tropical and subtropical regions results in immunological profiles with different responses to TB infection (Black et al. 2002). A U.S. study of refugees from TB-endemic countries (free of any acute illness or recent treatment history)
showed that among those latently infected with TB, those with concurrent helminth or *Helicobacter pylori* infections had raised levels of IFN-γ and other cytokines. *H. pylori* was associated with enhanced IFN-γ responses to TB (Perry et al. 2013). A recent review concluded that there is now strong evidence that helminth-induced T-cell responses impair defenses against *Mtb* infection, with consequences not only for disease prevalence and severity in different regions, but also with respect to TB vaccine efficacy (Rafi et al. 2012). However, there is murine data showing TB vaccine responses are unaffected by helminth-induced Th2 responses (Frantz et al. 2010) and that helminth infection does not exacerbate TB disease (Hubner et al. 2012). Another rodent model showed that prior helminth infections appear to illicit a macrophage response, which is protective during the early stages of mycobacterial infection (du Plessis et al. 2013).

Human studies in high- and low-burden helminth infection populations found no differences in tuberculin skin test responses in patients with and without helminth infections, or after treatment with albendazole (Pelly et al. 2005; Zevallos et al. 2010). Looking in more detail at components of the immune response, there is evidence for helminth-associated regulatory T cells suppressing responses to BCG (Bacillus Calmette-Guérin) vaccination in children (Wammes et al. 2010) and *Mtb*-specific Toll-like receptor expression in adults (Babu et al. 2009). Ex vivo studies in which monocytes differentiated into dendritic cells and macrophages, and then stimulated in vitro with live

<table>
<thead>
<tr>
<th>Social determinants</th>
<th>Clinically observed associations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Living conditions</strong></td>
<td><strong>Other communicable diseases</strong></td>
</tr>
<tr>
<td>Poverty</td>
<td>HIV/AIDS</td>
</tr>
<tr>
<td></td>
<td>Sexually transmitted infections</td>
</tr>
<tr>
<td></td>
<td>Infections linked to injection drug use</td>
</tr>
<tr>
<td></td>
<td>Acute lung infections (viral, bacterial, fungal)</td>
</tr>
<tr>
<td></td>
<td>Chronic helminth infestations</td>
</tr>
<tr>
<td></td>
<td><strong>Noncommunicable diseases</strong></td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>Chronic lung disease (e.g., COPD, pneumoconiosis)</td>
</tr>
<tr>
<td></td>
<td>Chronic kidney disease or end stage renal failure</td>
</tr>
<tr>
<td></td>
<td>Gut malabsorption or gastric bypass surgery</td>
</tr>
<tr>
<td></td>
<td>Skin disorders (e.g., psoriasis, alopecia areata)</td>
</tr>
<tr>
<td></td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td></td>
<td>Congenital and other immunodeficiencies</td>
</tr>
<tr>
<td></td>
<td>Autoimmune diseases</td>
</tr>
<tr>
<td></td>
<td>Solid organ transplants</td>
</tr>
<tr>
<td></td>
<td>Cancers</td>
</tr>
<tr>
<td></td>
<td><strong>Immunosuppressive therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Steroids (e.g., prednisone, methylprednisolone)</td>
</tr>
<tr>
<td></td>
<td>Antimetabolites (e.g., methotrexate, azathioprine)</td>
</tr>
<tr>
<td></td>
<td>T-cell inhibitors (e.g., cyclosporin, tacrolimus)</td>
</tr>
<tr>
<td></td>
<td>Alkylation agents (e.g., cyclophosphamide)</td>
</tr>
<tr>
<td></td>
<td>Biologicals (e.g., anti-TNF-α drugs, IL-2 blockers)</td>
</tr>
<tr>
<td></td>
<td><strong>Pregnancy and childbirth</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Extremes of age</strong></td>
</tr>
<tr>
<td></td>
<td>Elderly</td>
</tr>
<tr>
<td></td>
<td>Very young</td>
</tr>
</tbody>
</table>

**Table 4.** Social determinants and clinically observed associations with the development of tuberculosis
Table 5. Priorities for integration of tuberculosis care with that of other communicable and noncommunicable diseases (CDs and NCDs)

**TB and HIV services**

*Joint services*
- Family clinics for family diseases
- Optimized infection control

*Pragmatic screening and active case-finding strategies*
- HIV patients regularly screened for TB and all TB patients routinely tested for HIV infection, especially where HIV prevalence exceeds 1%
- Screening package to include weight and growth monitoring, blood pressure, blood sugar/HbA1c, and cholesterol if indicated

**TB and diabetes programs**

*Pragmatic screening and active case-finding strategies*
- All diabetes patients regularly screened for TB, and TB patients routinely tested for diabetes (random glucose of Hba1c), especially in highly prevalent areas

*Enhanced disease control*
- Shared treatment supervision (e.g., DOT for diabetes and TB)

**TB, smoking cessation, and chronic respiratory care**
- Linking smokers diagnosed with TB to smoking cessation programs
- Linking TB patients with chronic lung disease to ongoing respiratory care
- Supporting and enhancing existing PAL projects
- Regular TB screening in smokers/people with COPD (especially in TB endemic areas)

**TB and alcohol/substance abuse care programs**
- Screening for harmful drinking and alcohol use disorder in TB patients
- Linking TB patients with abuse problems to outreach and other care programs
- Increasing TB risk awareness and symptom-identification in substance abuse program

**Maternal and child health initiatives and services**

*Antenatal and obstetric services*
- Routine screening for HIV, TB, malaria (in endemic areas), DM, and hypertension
- Routine STD screening
- Administration of BCG vaccination to newborns

*Child health*
- Routine administration of expanded EPI with hepatitis B, *Haemophilus influenza* type B, pneumococcal, rotavirus, and HPV vaccines
- Regular monitoring and mapping of weight gain on a "Road to Health chart"
- Inclusion of pediatric TB in integrated management of childhood illness (IMCI) approaches
- Regular deworming

**Public health and advocacy campaigns**
- Reduce poverty and deprivation
- Promote healthy living
- Reduce cigarette smoking (tobacco control), solid fuel use
- Reduce excessive alcohol use/substance abuse
- Improve health literacy

Modified and adapted from Marais et al. 2013, with permission.
microfilariae, resulted in cytokine and chemokine expression that would impair the immune response (Talaat et al. 2006). But do these cell responses translate to poorer clinical outcomes? One large well-controlled trial found that treatment of helminths did not affect vaccine responses in Ugandan children (Webb et al. 2011).

NEED FOR INTEGRATED STRATEGIES

With diminishing investment in global health, integrated solutions should seek to unlock latent synergies and optimize resource utilization. It is particularly important to encourage local ownership and increase equitable domestic investment in health and sustainable development. Rates of TB provide a useful barometer as an “indicator disease” of socioeconomic inequality and deprivation (see Table 4). However, meeting the social and medical care needs of vulnerable communities requires a cohesive response from multiple role players. Within the emerging post-2015 development framework, it is essential to emphasize the strong link between health and responsible development, with TB being an “indicator disease” of socioeconomic inequality and deprivation (see Table 4). However, meeting the social and medical care needs of vulnerable communities requires a cohesive response from multiple role players. Within the emerging post-2015 development framework, it is essential to emphasize the strong link between health and responsible development, with TB providing a classic example of two-way causality. Governments need to develop national health strategic plans that integrate surveillance, diagnostic, and treatment systems to meet the challenges posed by current CD and NCD epidemics including new epidemics and drug-resistant infections. Priorities for integration and alignment of TB care with that of other communicable and noncommunicable diseases (CDs and NCDs) are listed in Table 5. Wider integration of TB control activities presents opportunities to explore latent synergies and getting convergence for achieving universal health care within programs.

ACKNOWLEDGMENTS

Support from the European Commission FW7 Rd-RTI Project; European and Developing Countries Clinical Trials Partnership, The Hague, Netherlands (EDCTP grants REMOX, PANACEA, and TB-NEAT); UBS Optimus Foundation, Switzerland; NIHR Biomedical Research Centre, University College London Hospital, London, UK; and Australian NHMRC and the Centre for Research Excellence in Tuberculosis. We are grateful to Mr. Adam Zumla for technical and search strategy support and to Dr. Knut Lonroth, Global TB Department, WHO, Geneva for providing data and Figure 1.

REFERENCES


REFERENCES


REFERENCES


REFERENCES


ACKNOWLEDGMENTS

Support from the European Commission FW7 Rd-RTI Project; European and Developing Countries Clinical Trials Partnership, The Hague, Netherlands (EDCTP grants REMOX, PANACEA, and TB-NEAT); UBS Optimus Foundation, Switzerland; NIHR Biomedical Research Centre, University College London Hospital, London, UK; and Australian NHMRC and the Centre for Research Excellence in Tuberculosis. We are grateful to Mr. Adam Zumla for technical and search strategy support and to Dr. Knut Lonroth, Global TB Department, WHO, Geneva for providing data and Figure 1.

REFERENCES


ACKNOWLEDGMENTS

Support from the European Commission FW7 Rd-RTI Project; European and Developing Countries Clinical Trials Partnership, The Hague, Netherlands (EDCTP grants REMOX, PANACEA, and TB-NEAT); UBS Optimus Foundation, Switzerland; NIHR Biomedical Research Centre, University College London Hospital, London, UK; and Australian NHMRC and the Centre for Research Excellence in Tuberculosis. We are grateful to Mr. Adam Zumla for technical and search strategy support and to Dr. Knut Lonroth, Global TB Department, WHO, Geneva for providing data and Figure 1.

REFERENCES


Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases

Matthew Bates, Ben J. Marais and Alimuddin Zumla

Cold Spring Harb Perspect Med 2015; doi: 10.1101/cshperspect.a017889 originally published online February 6, 2015

Subject Collection  Tuberculosis

Transmission and Institutional Infection Control of Tuberculosis
Edward A. Nardell

Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection
Katrin D. Mayer-Barber and Daniel L. Barber

Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases
Matthew Bates, Ben J. Marais and Alimuddin Zumla

Host-Directed Therapies for Tuberculosis
David M. Tobin

Immunity and Immunopathology in the Tuberculous Granuloma
Antonio J. Pagán and Lalita Ramakrishnan

Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm?
Sumit Chakraborty and Kyu Y. Rhee

Genetic Approaches to Facilitate Antibacterial Drug Development
Dirk Schnappinger

The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Khisimuzi Mdluli, Takushi Kaneko and Anna Upton

Clinical Aspects of Adult Tuberculosis
Robert Loddenkemper, Marc Lipman and Alimuddin Zumla

Advances in Diagnostic Assays for Tuberculosis
Stephen D. Lawn

Diagnosis and Management of Latent Tuberculosis Infection
Laura Muñoz, Helen R. Stagg and Ibrahim Abubakar

Mycobacterial Growth
Iria Uhía, Kerstin J. Williams, Vahid Shahrezaei, et al.

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Kwonjune J. Seung, Salmaan Keshavjee and Michael L. Rich

The Mycobacterial Cell Wall—Peptidoglycan and Arabinogalactan

Tuberculosis and HIV Coinfection
Judith Bruchfeld, Margarida Correia-Neves and Gunilla Källenius

Imaging in Tuberculosis

For additional articles in this collection, see http://perspectivesinmedicine.cshlp.org/cgi/collection/

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved